150 related articles for article (PubMed ID: 8700537)
21. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.
Skilling JS; Squatrito RC; Connor JP; Niemann T; Buller RE
Gynecol Oncol; 1996 Jan; 60(1):72-80. PubMed ID: 8557231
[TBL] [Abstract][Full Text] [Related]
22. p53 expression, mutation, and allelic deletion in ovarian cancer.
McManus DT; Yap EP; Maxwell P; Russell SE; Toner PG; McGee JO
J Pathol; 1994 Nov; 174(3):159-68. PubMed ID: 7823248
[TBL] [Abstract][Full Text] [Related]
23. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
[TBL] [Abstract][Full Text] [Related]
24. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.
Hartmann A; Blaszyk H; McGovern RM; Schroeder JJ; Cunningham J; De Vries EM; Kovach JS; Sommer SS
Oncogene; 1995 Feb; 10(4):681-8. PubMed ID: 7862445
[TBL] [Abstract][Full Text] [Related]
25. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
26. Improved detection of p53 point mutations by dideoxyfingerprinting (ddF).
Martincic D; Whitlock JA
Oncogene; 1996 Nov; 13(9):2039-44. PubMed ID: 8934553
[TBL] [Abstract][Full Text] [Related]
27. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
28. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.
Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349
[TBL] [Abstract][Full Text] [Related]
29. Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma.
Chen TC; Hsieh LL; Kuo TT
J Pathol; 1995 Jul; 176(3):243-7. PubMed ID: 7674087
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
31. p53 alterations in chemically induced hamster cheek-pouch lesions.
Gimenez-Conti IB; LaBate M; Liu F; Osterndorff E
Mol Carcinog; 1996 Aug; 16(4):197-202. PubMed ID: 8784462
[TBL] [Abstract][Full Text] [Related]
32. Establishment and characterization of human ovarian carcinoma cell lines.
Yuan Y; Kim WH; Han HS; Lee JH; Park HS; Chung JK; Kang SB; Park JG
Gynecol Oncol; 1997 Sep; 66(3):378-87. PubMed ID: 9299249
[TBL] [Abstract][Full Text] [Related]
33. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
34. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou ES; Levesque MA; Katsaros D; Angelopoulou K; Yu H; Genta F; Arisio R; Massobrio M; Bharaj B; Diamandis EP
Anticancer Res; 1999; 19(1B):749-56. PubMed ID: 10216487
[TBL] [Abstract][Full Text] [Related]
35. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
36. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K- ras mutation.
Wang Y; Yamaguchi Y; Watanabe H; Ohtsubo K; Wakabayashi T; Sawabu N
J Gastroenterol; 2002; 37(10):831-9. PubMed ID: 12424567
[TBL] [Abstract][Full Text] [Related]
38. [Detection of p53 mutation using PCR-SSCP silver staining method].
Zhao W; Si J; Li K; Zhang X; Song G
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Jun; 17(3):219-22. PubMed ID: 8706159
[TBL] [Abstract][Full Text] [Related]
39. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay.
Kashiwazaki H; Tonoki H; Tada M; Chiba I; Shindoh M; Totsuka Y; Iggo R; Moriuchi T
Oncogene; 1997 Nov; 15(22):2667-74. PubMed ID: 9400993
[TBL] [Abstract][Full Text] [Related]
40. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
